Medicare Could Jumpstart Our Failing Biosimilars Markets
US consumers are missing out on the lower prices that come from biosimilars - copies of important biologic therapies that are permitted once the innovator product goes off patent. The Medicare program could help create this market - and save billions for taxpayers at the same time.